Insmed Incorporated (LON:0JAV)
London flag London · Delayed Price · Currency is GBP · Price in USD
81.39
-2.44 (-2.91%)
At close: Feb 21, 2025

Insmed Statistics

Total Valuation

Insmed has a market cap or net worth of GBP 11.61 billion. The enterprise value is 11.51 billion.

Market Cap 11.61B
Enterprise Value 11.51B

Important Dates

The last earnings date was Thursday, February 20, 2025.

Earnings Date Feb 20, 2025
Ex-Dividend Date n/a

Share Statistics

Current Share Class n/a
Shares Outstanding n/a
Shares Change (YoY) +16.81%
Shares Change (QoQ) +3.05%
Owned by Insiders (%) n/a
Owned by Institutions (%) n/a
Float 164.79M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
PB Ratio n/a
P/TBV Ratio 122.61
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings -15.77
EV / Sales 40.00
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF -20.41

Financial Position

The company has a current ratio of 5.45, with a Debt / Equity ratio of 4.59.

Current Ratio 5.45
Quick Ratio 4.99
Debt / Equity 4.59
Debt / EBITDA n/a
Debt / FCF -1.86
Interest Coverage -9.24

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -29.31%
Return on Invested Capital (ROIC) -37.49%
Return on Capital Employed (ROCE) -45.53%
Revenue Per Employee 228,575
Profits Per Employee -574,267
Employee Count 912
Asset Turnover 0.22
Inventory Turnover 0.94

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +181.35% in the last 52 weeks. The beta is 1.12, so Insmed's price volatility has been higher than the market average.

Beta (5Y) 1.12
52-Week Price Change +181.35%
50-Day Moving Average 74.47
200-Day Moving Average 68.45
Relative Strength Index (RSI) 59.40
Average Volume (20 Days) 1,700

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) 7.94

Income Statement

In the last 12 months, Insmed had revenue of GBP 290.52 million and -729.89 million in losses. Loss per share was -4.45.

Revenue 290.52M
Gross Profit 222.03M
Operating Income -628.29M
Pretax Income -726.93M
Net Income -729.89M
EBITDA -621.20M
EBIT -628.29M
Loss Per Share -4.45
Full Income Statement

Balance Sheet

The company has 1.15 billion in cash and 1.05 billion in debt, giving a net cash position of 98.95 million.

Cash & Cash Equivalents 1.15B
Total Debt 1.05B
Net Cash 98.95M
Net Cash Per Share n/a
Equity (Book Value) 227.95M
Book Value Per Share 1.27
Working Capital 1.06B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -546.26 million and capital expenditures -17.51 million, giving a free cash flow of -563.78 million.

Operating Cash Flow -546.26M
Capital Expenditures -17.51M
Free Cash Flow -563.78M
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross margin is 76.43%, with operating and profit margins of -216.26% and -251.24%.

Gross Margin 76.43%
Operating Margin -216.26%
Pretax Margin -250.22%
Profit Margin -251.24%
EBITDA Margin -213.82%
EBIT Margin -216.26%
FCF Margin n/a

Dividends & Yields

Insmed does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -16.81%
Shareholder Yield -16.81%
Earnings Yield -6.29%
FCF Yield -4.86%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Insmed has an Altman Z-Score of -0.28. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -0.28
Piotroski F-Score n/a